Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- PayPal lifts full-year profit guidance; Q3 revenue falls short
- Corning shares rise 3% in premarket trade after Q3 EPS, revenue beat estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
